Influential factors in the appearance of Erectile Dysfunction
DOI:
https://doi.org/10.19230/jonnpr.2016.1.3.1024Keywords:
Erectile dysfunction, Obesity, Hypertension, Hypercholesterol, Mellitus diabetes.Abstract
Objectives: Determine erectile dysfunction (ED) prevalence in patients with cardiovascular risk factors (CVRF). Assess ED incidence in relation to the extent of controlling CVRF.
Methodology: An observational, descriptive, analytical, cross-sectional study. Resulting in a sample of 210 people, of which 31 could not complete the study for various reasons (change of address, death, refused to complete questionnaire, etc.).
Variables analysis.
We analysed: Age, Level of education, Civil status, Height, Weight and Body mass index (BMI), SBP, DBP, Smoking habit, No. cigarettes/day, year smoking began, ex-smoker, year smoking stopped, Alcohol consumption, grams alcohol/week. Consumption of
other drugs, frequency and type. Blood test: glucose, haemoglobin glycated haemoglobin, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, artherogenic index, creatinine, urea, GOT, GPT, gamma-GT and PSA. Urine test: microalbuminuria, proteinuria and creatinine clearance. ECG. Diabetes diagnosed at least one year ago and prescribed drugs to treat it. High blood pressure diagnosed at least one year ago and prescribed drugs to treat it. Dyslipidaemia (hypercholesterolaemia) diagnosed at least one year ago and prescribed drugs to treat it. Concomitant diseases of at least one year and drugs (up to 3) .
Results: Of the 210 selected people, 179 completed the questionnaire (85.2%). The mean age was 64.5 ± 11.6 years. When analysing all the study variables in relation to the main variable, presence or absence of ED, age is seen to play an important
role in ED appearing as ED incidence rises with age. Blood pressure had no significant relationship with the studied variable, and the same can be said of BMI and its subdivision into normal weight and obesity. As regards toxic habits, neither cigarette smoking nor alcohol consumption influenced the presence of ED. The same may be said of the sociological-type variables (civil states, level of education). Regarding the biochemical variables from blood tests, a significant relationship with the atherogenic index and its recoded variable at high and low atherogenic risk (p< 0.04) was noted. In the glycaemic profile, a glycaemia mean of 126 mg/dl was obtained in the ED presence group, which is the cut-off point proposed by ADA (American Diabetes Association) to consider a subject diabetic. Likewise, glycated haemoglobin presented figures in the 2 groups that can be considered an alternation of a practically diabetic glucose metabolism.
In our study, the presence of diabetic diseases, HBP (high blood pressure) and dyslipidaemia showed no significant relationship with ED presence for each disease.
Conclusions: In our study of cardiovascular risk factors such as hypertension, diabetes mellitus, or hypercholesterolemia show no relation to the appearance of erectile dysfunction.
Downloads
References
Juan I. Martínez-Salamanca, Claudio Martínez-Ballesteros, Luis Portillo, Sonia Gabancho,
Ignacio Moncada1 y Joaquín Carballido. MONOGRÁFICO: DISFUNCIÓN ERÉCTIL. Arch. Esp. Urol. 2010; 63
(8): 581-588
Lue TF. Erectile dysfunction. N Engl J Med, 2000; 342: 1802 Dean RC and Lue TF. Physiology of penile erection
and pathophysiology of erectile dysfunction. Urol Clin North Am, 2005; 32: 379.
Moreira Machado A: Etiopatogenia de la Disfunción eréctil. En Arrondo Arrondo JL “Actualización en Andrología”.
Servicio Navarro de Salud 1999: 224-239.
Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile
dysfunction:results of the ‘Cologne Male Survey’. Int J Impot Res 2000 Dec;12(6):305-
http://www.ncbi.nlm.nih.gov/pubmed/11416833
Martin Morales A, Sánchez Cruz JJ, Saenz de Tejada I, Rodríguez Vela L, Jiménez-Cruz JF, Burgos-Rodríguez
R: Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiología de la
Disfunción Eréctil Masculina Study. J Urol 2001; 166: 569-575.
Guirao Sánchez L, García-Giralda Ruiz L, Sandoval Martínez C, Mocciaro Loveccio A:Disfunción eréctil en
atención primaria como marcador del estado de salud: factores asociados y respuesta al sildenafilo. Aten
Primaria 2002. 30: 290-296.
Pomerol Monseny JM., Principios básicos en el diagnóstico de la disfunción eréctil. En: Arrondo Arrondo JL
“Actualización en Andrología”. Servicio Navarro de Salud 1999: 259-265.
Gades NM, Nehra A, Jacobson DJ, McGree ME, Ghirman CJ, Rhodes T, Roberts RO, Liebre MM and Jacobsen
SJ: Association between smoking and erectile dysfunction: A population-based study. Am J Epidemiol 2005; 161:
-351.
Rodríguez Vela L: Impotencia e hipertensión arterial. Med Clin (Barc) 2002; 119: 534-6.
Cuéllar de León AJ, Ruíz García V, Campos González JC, Pérez Hoyos S, Brotons Multó F:Prevalencia de la
disfunción eréctil en pacientes con hipertensión arterial. Med Clin (Barc) 2002; 119: 521-6.
Burchardt M, Burchardt T, Baer L, Kiss AJ, Pawar RV, Shabsigh A et al: Hipertensión is associated with severe
erectile dysfunction. J Urol 2000; 164: 1188-91.
Enzlin P, Chantal M, Van Der Cruel A, Vanderschueren V, Demyttenaere K: Prevalence and predictors of sexual
dysfunction in patients with type 1 Diabetes. Diabetes Care 2003; 26:409-14
Romeo JH, Seftel AD, Madhun ZT, Aron DC: Sexual function in men with diabetes type 2: association with
glycemic control. J Urol 2000; 163: 788-91.
Gokkaya SC , Ozden C , Levent Ozdal O , Hakan Koyuncu H , Guzel O , Memis A. Effect of correcting serum
cholesterol levels on erectile function in patients with vasculogenic erectile dysfunction. Scand J Urol Nephrol.
;42(5):437-40. doi: 10.1080/00365590801950279.
Kumsar NA, Kumsar
Mar 4. doi: 10.1111/and.12566. PMID: 26940022
Fuster Bellido T, Martínez Ques D, Faus Mascarell E, Colominas Sarrió P, Plá Vallá R. y Arlandis Puig A:
Disfunción eréctil. Prevalencia y factores de riesgo asociados. Sexología Integral 2006; 3: 210-212.
Cruz Navarro N: Alternativas actuales en la terapia oral de la Disfunción Eréctil. En Arrondo Arrondo JL:
“Actualización en Andrología”. Servicio Navarro de Salud.1999: 266-286.
Cheng QS, Liu T, Huang HB, Peng YF, Jiang SC, Mei XB. Association between personal basic information, sleep
quality, mental disorders and erectile function: a cross-sectional study among 334 Chinese outpatients.
Andrologia. 2016 Jun 30. doi: 10.1111/and.12631.
Rance J, Phillips C, Davies S, et al. How much of a priority is treating erectile dysfunction: a study of patients’
perceptions. Diabet Med 2003; 20: 205-9.
Artigao Rodenas LM. Prevalencia de factores de riesgo cardiovascular en la provincia de Albacete. Tesis
Doctoral. Universidad Autónoma de Madrid. 1997: 125-155.
González-Juanatey JR et al. Prevalencia y características de la dislipemia en pacientes en prevención primaria y
secundaria tratados con estatinas en España. Estudio DYSIS-España. Rev Esp Cardiol. 2011;64(4):286-94.
National Cholesterol Education Program. Executive Summary of the Tird Report of the National Cholesterol
Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In
Adults (Adult Treatment Panel III). JAMA 2001;285: 2486-2497.
Villamil Cajoto I, Díaz Peromingo JA, Sánchez Leira J, García Suárez F, Saborido Forjan J,Iglesias Gallego M:
Disfunción eréctil: un problema poco valorado en Medicina Interna. Estudio de pacientes y medicación
relacionada. An Med Inter (Madrid) 2006. 23: 115-118.
Brock G, Ni X, Oelke M, Mulhall J, Rosenberg M, Seftel A, D'Souza D, Barry J. Efficacy of Continuous Dosing of
Tadalafil Once Daily vs Tadalafil On Demand in Clinical Subgroups of Men With Erectile Dysfunction: A
Descriptive Comparison Using the Integrated Tadalafil Databases. J Sex Med. 2016 May;13(5):860-75. doi:
1016/j.jsxm.2016.02.171.
Lebovitz HE: Secretagogos de insulina. En “Diabetes Mellitus. Fundamentos y Clínica” (Le Roith D, Taylor SI &
Olefsky JM eds). 2ª edición. México. Mcgraw Hill.2003: 960-70.
Foyt HL, Ghazzi MN, Hanley RM, et al: Tiazolidindionas, en “Diabetes Mellitus.
Fundamentos y clínica” (Le Roith D, Taylor SI & Olefsky JM eds). 2ª edición. México. McGraw Hill. 2ª edición
: 982-92.
López Rubio MA, Tárraga López PJ, Rodríguez Montes JA, Frías López MC, Solera Albero J, Bermejo López P.
Alteración del perfil lipídico y del riesgo cardiovascular en pacientes con Hipotiroidismo subclínico.
JONNPR.2016;1(2):45-49. DOI: DOI: 10.19230/jonnpr.2016.1.2.970
Llisterri Caro JL, Sánchez Sánchez F, Brotons Muntó F: Disfunción sexual en la hipertensión arterial.
Hipertensión 2005; 22: 59-72.
Cuellar de León AJ, Campos González JC, Brotons Muntó F et al. Hipertensión arterial y disfunción eréctil. Grupo
de Urología de la SVMFYC 2005.
Chaudhary RK, Shamsi BH, Chen HM, Tan T, Tang KF, Xing JP. Risk factors for erectile dysfunction in patients
with cardiovascular disease. J Int Med Res. 2016 Jun;44(3):718-27. doi: 10.1177/0300060515621637.
Culebras JM. Resultados negativos, cincuenta por ciento del conocimiento. JONNPR. 2016;1(1):1-2. DOI:
19230/jonnpr.2016.1.1.926
Published
Issue
Section
License
All accepted originals remain the property of JONNPR. In the event of publication, the authors exclusively transfer their rights of reproduction, distribution, translation and public communication (by any sound, audiovisual or electronic medium or format) of their work. To do so, the authors shall sign a letter transferring these rights when sending the paper via the online manuscript management system.
The articles published in the journal are freely used under the terms of the Creative Commons BY NC SA license, therefore.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
